These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38261390)

  • 61. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort.
    Quintana R; Pons-Estel GJ; Roberts K; Sacnún M; Serrano R; Nieto R; Conti S; Gervasoni V; Catoggio LJ; Soriano ER; Scolnik M; García MA; Alvarellos A; Saurit V; Berbotto GA; Sato EI; Costallat LTL; Neto EFB; Bonfa E; Xavier RM; de Oliveira E Silva Montandon AC; Molina-Restrepo JF; Iglesias-Gamarra A; Guibert-Toledano M; Reyes-Llerena GA; Massardo L; Neira OJ; Cardiel MH; Barile-Fabris LA; Amigo MC; Silveira LH; Torre IG; Acevedo-Vásquez EM; Ugarte-Gil MF; Alfaro-Lozano JL; Segami MI; Chacón-Díaz R; Esteva-Spinetti MH; Gomez-Puerta JA; Alarcón GS; Pons-Estel BA
    Lupus; 2020 Aug; 29(9):1140-1145. PubMed ID: 32605527
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis.
    Kisaoglu H; Baba O; Kalyoncu M
    Pediatr Nephrol; 2023 Apr; 38(4):1167-1175. PubMed ID: 36156735
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Arthritis Res Ther; 2020 Jan; 22(1):8. PubMed ID: 31924267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort.
    A Mohammed RH; Lotfy Fayed H; Ibrahim Emara N
    Lupus; 2022 Apr; 31(5):628-636. PubMed ID: 35306918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
    Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort.
    Cann MP; Sage AM; McKinnon E; Lee SJ; Tunbridge D; Larkins NG; Murray KJ
    Lupus; 2022 Feb; 31(2):246-255. PubMed ID: 35037500
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The association of psychosocial stressors and psychiatric disorders with fatigue in systemic lupus erythematosus patients.
    Andayani S; Kumoroyekti T; Pradana K; Hamijoyo L
    Lupus; 2022 Oct; 31(12):1491-1497. PubMed ID: 35998900
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
    Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
    Mok CC; Ho LY; Tse SM; Chan KL
    Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 74. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study.
    Abe K; Ishikawa Y; Kita Y; Yajima N; Inoue E; Sada KE; Miyawaki Y; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M
    Arthritis Res Ther; 2022 Jul; 24(1):179. PubMed ID: 35902976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
    Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study.
    Cheng CF; Huang YM; Lu CH; Hsieh SC; Li KJ
    Lupus; 2019 Dec; 28(14):1699-1704. PubMed ID: 31640531
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities.
    Kang JH; Shin MH; Choi SE; Xu H; Park DJ; Lee SS
    Rheumatology (Oxford); 2021 Feb; 60(2):762-766. PubMed ID: 32793984
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.